GeoVax Labs, Inc. Announces Upcoming Investor Events!
GeoVax Labs to Present at Major Investor Conferences
GeoVax Labs, Inc. (Nasdaq: GOVX), a pioneering biotechnology company focused on developing innovative immunotherapies and vaccines for cancers and infectious diseases, is making waves as it prepares for two significant investor conferences. The presentations will be led by David Dodd, the company’s Chairman and CEO.
H.C. Wainwright 26th Annual Global Investment Conference
GeoVax is slated to present at the H.C. Wainwright 26th Annual Global Investment Conference. During this event, David Dodd will share insights into the company’s progress and future strategies. The session is scheduled for an early morning slot on September 9, 2024, at 7:00 a.m. ET. The conference will take place at an iconic venue in New York City, allowing for a vibrant exchange of ideas and networking opportunities.
One-on-One Meetings
Additionally, senior management from GeoVax will be engaging in one-on-one meetings with registered attendees. Those interested in discussing the company’s initiatives can reach out through the conference portal or contact the company directly at info@geovax.com.
Emerging Growth Conference
Following the H.C. Wainwright event, GeoVax will also take part in the Emerging Growth Conference on September 25, 2024, at 2:55 p.m. ET. This conference will be held virtually, making it accessible to a broader audience. Here, Dodd will continue to highlight the company's corporate updates and advancements in its clinical programs.
Webcast Available
A webcast link will be provided for those wishing to follow along remotely, ensuring that investors can stay informed about the robust initiatives GeoVax is pursuing within the biotech landscape.
About GeoVax
GeoVax Labs, Inc. is on the cutting edge of biotechnology, focusing on developing novel vaccines that tackle some of the world’s most pressing infectious diseases. In addition to infectious disease solutions, the company is advancing therapies for solid tumor cancers. The flagship program within their portfolio is GEO-CM04S1, an advanced COVID-19 vaccine currently being evaluated in multiple Phase 2 clinical trials. Recently, GeoVax secured a BARDA-funded contract to support a significant Phase 2b clinical trial involving 10,000 participants, assessing GEO-CM04S1's efficacy against an approved COVID-19 vaccine.
Furthermore, GEO-CM04S1 is evaluated in specific patient populations, including those with hematologic cancers who have limited options with current vaccines. In cancer therapy, GeoVax is advancing a novel oncolytic therapy named Gedeptin®, being tested in a multicenter Phase 1/2 trial for advanced head and neck cancers. With a formidable intellectual property portfolio supporting its efforts, GeoVax holds widespread rights to its technologies and products.
Company Contact Details
Company Contact: info@geovax.com | 678-384-7220
Investor Relations Contact: austin.murtagh@precisionaq.com | 212-698-8696
Media Contact: sr@roberts-communications.com | 202-779-0929
Frequently Asked Questions
What is GeoVax Labs, Inc. known for?
GeoVax is known for developing groundbreaking immunotherapies and vaccines targeting infectious diseases and cancers.
Who will represent GeoVax at the investor conferences?
David Dodd, the Chairman and CEO of GeoVax, will be presenting at both conferences.
When are the upcoming investor events?
The events are scheduled for September 9 and September 25, 2024.
How can I attend the presentations?
The presentations will be available via webcast, and one-on-one meetings can be arranged through the conference portals.
What is the primary focus of GeoVax’s clinical trials?
The clinical trials primarily focus on advancing a next-generation COVID-19 vaccine and innovative therapies for various cancers.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Leinco Technologies Inc. Expands Portfolio with QED Biosciences
- Berkshire Hathaway Hits $1 Trillion, What's Next for Investors?
- UC Asset LP Announces Management-Driven Stock Buyback Plan
- NXG Cushing Midstream Energy Fund (NYSE: SRV) Announces New Distributions
- NXG NextGen Infrastructure Income Fund Announces New Distributions
- VAST Resources Plc Announces Major Holdings Notification
- Park Street A/S Announces Treasury Shares Update
- Park Street A/S Announces Significant Shareholding Changes
- Music Licensing, Inc. Expands Portfolio with New Acquisition
- EzFill Holdings, Inc. Achieves NASDAQ Listing Compliance Again
- DemandScience Achieves a Historic 11th Inc. 5000 Honor
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
- RDE, Inc. Changes Ticker Symbol to GIFT for Growth
- NMI Holdings, Inc. Investor Day Scheduled for November 2024
- Alto Ingredients, Inc. to Present at H.C. Wainwright Conference
- LM Funding America, Inc. Gears Up for H.C. Wainwright Conference
- Mount Logan Capital Inc. Expands Workforce with New Hire
- Avenue Therapeutics Announces Participation in Investor Conferences
- Y-mAbs Therapeutics to Present at Key Investor Conferences
- Alexandria Real Estate Equities Announces Q3 2024 Results Call
- Senti Bio Hosts Key Investor Conferences This Fall
- Enviri Corporation Prepares for Key Investor Conferences
- Processa Pharmaceuticals and Upcoming Industry Conferences
- Compass Therapeutics Engages Investors at Upcoming Events
- Clene Inc. Prepares for H.C. Wainwright Investment Event
Recent Articles
- Autonomous Cars Forecast: Growth to USD 43.44 Billion By 2032
- Cemat A/S Unveils Managerial Share Transactions Update
- UK Home Prices Expected to Rise, Boosting First-Time Buyer Affordability
- Ulta Beauty Faces Challenges: Time to Seize Investment Opportunities
- Top Three High-Yield Dividend Stocks to Buy Now
- IRS Audit Rates: Insights on Wealthy Taxpayer Scrutiny
- Global NGS Sample Preparation Market Poised for Growth
- Light The Night: Illuminate Hope for Blood Cancer Patients
- GSE Worldwide Receives Strategic Investment to Fuel Growth
- gRNA Market Growth Driven by CRISPR-Cas9 and Innovation
- Growth Projections in Global Industrial Distribution Market
- Simtra BioPharma Solutions Welcomes Dr. Mike Schaefers
- Cassava Sciences to Shine at H.C. Wainwright Conference
- Enviri Corporation Prepares for Key Investor Conferences
- EmergeOrtho-Triangle Region Welcomes Dr. Kyle E. Nappo, M.D.
- Soligenix Secures European Patent for Synthetic Hypericin Production
- Video Conferencing Solutions Market to Hit $49.7 Billion by 2032
- Unicycive Therapeutics Submits NDA for Oxylanthanum Carbonate
- Danske Bank A/S Updates on Managerial Transactions - 2024
- Exploring Growth in the Buy Now Pay Later Market
- Embecta Secures FDA Clearance for Diabetes Patch Pump
- Probe Gold Achieves High-Grade Gold Intersections in Quebec
- Albion Enterprise VCT PLC Reports Strong Interim Results
- Citi Highlights Dire Challenges Facing China's Economy
- Barclays Upgrades Deutsche Bank to Overweight Amid Optimism